Bowel Obstruction from GLP-1 Medications in District of Columbia
Last Updated: April 1, 2026
Bowel Obstruction cases linked to GLP-1 medications are being filed by District of Columbia residents. The District of Columbia's three-year statute of limitations for both personal injury and product liability claims gives residents additional time to pursue Depo-Provera and GLP-1 medication injury cases. As the nation's capital, D.C. is home to federal regulatory agencies including the FDA, and its courts are familiar with pharmaceutical regulatory issues. The District's concentrated urban population and extensive medical infrastructure mean many residents have been prescribed these medications through local health systems.
Bowel Obstruction has been linked to GLP-1 medications including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity. District of Columbia residents who developed bowel obstruction after using these drugs may qualify for compensation. The product liability statute of limitations in District of Columbia is 3 years. Cases are pending in federal MDL, and attorneys handle claims on a contingency fee basis — no cost unless you win.
Bowel Obstruction and GLP-1 Medications
Bowel obstruction occurs when a blockage in the small or large intestine prevents the normal passage of food, fluids, and gas. For District of Columbia residents who developed bowel obstruction after using GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity, this condition represents a medical emergency that can be life-threatening if not treated promptly. Symptoms include severe cramping pain, abdominal distension, inability to pass gas or stool, and persistent vomiting. Treatment frequently requires emergency surgery to remove the obstruction and repair damaged intestinal tissue. Some patients suffer permanent damage to their digestive system.
The manufacturers of these medications — Novo Nordisk (maker of Ozempic, Wegovy, and Rybelsus) and Eli Lilly (maker of Mounjaro and Trulicity) — are accused of failing to adequately warn patients and prescribing physicians about the risk of bowel obstruction. Despite internal data and emerging clinical evidence suggesting a causal link, the drug labels did not include sufficient warnings about the severity and potential permanence of this condition.
For District of Columbia residents, this means that if you developed bowel obstruction while taking a GLP-1 medication, you may have a valid product liability claim. The federal multidistrict litigation (MDL 3094) is consolidating these cases for efficient pretrial proceedings, while preserving each plaintiff's individual right to trial.
Recognizing Bowel Obstruction from GLP-1 Drugs
If you are a District of Columbia resident who used Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity and experienced any of the following symptoms, you may have developed bowel obstruction as a result:
Severe cramping abdominal pain
Inability to pass gas or stool
Swelling of the abdomen
Nausea and vomiting
Loss of appetite
Diagnosis
Bowel Obstruction is typically confirmed through x-ray or ct scan of the abdomen. If you are experiencing symptoms but have not yet received a formal diagnosis, an attorney can help coordinate appropriate medical evaluation as part of your case. Having documented medical evidence strengthens your claim significantly.
Filing a Bowel Obstruction Claim in District of Columbia
District of Columbia residents who developed bowel obstruction after using GLP-1 medications have specific legal options and deadlines. The statute of limitations for product liability claims in District of Columbia is 3 years, and the personal injury statute of limitations is 3 years.
Importantly, District of Columbia recognizes the discovery rule. This means the statute of limitations clock may not start until you knew or reasonably should have known that your bowel obstruction was caused by a GLP-1 medication. Given that the scientific understanding of the link between these drugs and bowel obstruction has evolved significantly in recent years, many District of Columbia residents may still be within their filing window even if their injury occurred some time ago.
Cases may be filed in the D.C. Superior Court at the state level or in federal court through the United States District Court for the District of Columbia. Most GLP-1 injury cases are being coordinated through the federal MDL for pretrial proceedings.
District of Columbia legal landscape: D.C. applies strict liability for defective products under Restatement (Second) of Torts Section 402A and follows a contributory negligence standard — one of the few jurisdictions where any plaintiff fault can completely bar recovery. Residents in Washington and surrounding areas should consult with an attorney to evaluate their potential bowel obstruction claim.
Personal Injury SOL
3 years
Product Liability SOL
3 years
Discovery Rule
Yes
GLP-1 Drugs Linked to Bowel Obstruction
The following GLP-1 receptor agonist medications have been linked to bowel obstruction in ongoing litigation. If you used any of these drugs in District of Columbia and developed bowel obstruction, you may qualify for a claim:
Ozempic
Semaglutide injection by Novo Nordisk. Prescribed for type 2 diabetes.
Wegovy
Semaglutide injection by Novo Nordisk. Prescribed for weight management.
Mounjaro
Tirzepatide injection by Eli Lilly. Prescribed for type 2 diabetes and weight management.
Rybelsus
Oral semaglutide by Novo Nordisk. Prescribed for type 2 diabetes.
Saxenda
Liraglutide injection by Novo Nordisk. Prescribed for weight management.
Trulicity
Dulaglutide injection by Eli Lilly. Prescribed for type 2 diabetes.
Do You Qualify for a Bowel Obstruction Claim in District of Columbia?
District of Columbia residents may be eligible to file a bowel obstruction claim if the following criteria apply:
Used a GLP-1 Medication
You were prescribed and used Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity or another GLP-1 receptor agonist medication.
Diagnosed with Bowel Obstruction
You received a medical diagnosis of bowel obstruction through x-ray or ct scan of the abdomen.
Injury Occurred After Drug Use
Your bowel obstruction developed after you began taking the GLP-1 medication, establishing a timeline consistent with causation.
Within District of Columbia's Filing Deadline
Your claim falls within District of Columbia's product liability statute of limitations (3 years). The discovery rule may extend this deadline. An attorney can evaluate your specific timeline.
Bowel Obstruction in District of Columbia: FAQ
What is bowel obstruction and how is it linked to GLP-1 medications in District of Columbia?
Blockage in the small or large intestine preventing food and fluids from passing. GLP-1 medications including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity have been linked to an increased risk of developing this condition. District of Columbia residents who were prescribed these medications and subsequently developed bowel obstruction may be eligible to file a lawsuit seeking compensation for their injuries, medical expenses, and other damages.
What are the symptoms of bowel obstruction caused by Ozempic or other GLP-1 drugs?
Common symptoms of bowel obstruction include severe cramping abdominal pain, inability to pass gas or stool, swelling of the abdomen, nausea and vomiting, loss of appetite. If you experienced these symptoms after taking Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity in District of Columbia, you should seek medical attention immediately and consider having your case evaluated for potential legal action.
How is bowel obstruction diagnosed for purposes of a GLP-1 lawsuit?
Bowel Obstruction is typically diagnosed through x-ray or ct scan of the abdomen. For District of Columbia residents filing a GLP-1 injury claim, medical documentation confirming your diagnosis is important for establishing your case. If you have not yet been formally diagnosed but are experiencing symptoms, your attorney can help coordinate appropriate medical evaluation.
What is the statute of limitations for a bowel obstruction claim in District of Columbia?
In District of Columbia, the statute of limitations for product liability claims is 3 years. District of Columbia recognizes the discovery rule, meaning the filing deadline may start from when you discovered or should have discovered that your bowel obstruction was caused by a GLP-1 medication. Consult with an attorney to determine your exact deadline.
What compensation can I receive for bowel obstruction caused by GLP-1 drugs in District of Columbia?
District of Columbia residents who qualify may recover compensation for medical expenses (including emergency treatment, surgery, hospitalization, and rehabilitation), lost wages, pain and suffering, emotional distress, and diminished quality of life. The amount depends on the severity of your bowel obstruction and its impact on your daily life.
Is there any cost to file a bowel obstruction claim in District of Columbia?
There is no upfront cost. Attorneys handling GLP-1 bowel obstruction cases in District of Columbia work on a contingency fee basis, meaning they only receive payment if you receive compensation through settlement or trial verdict. NuLegal's initial case review is completely free with no obligation.
Other GLP-1 Injuries in District of Columbia
District of Columbia Residents: Get Your Free Case Review
If you developed bowel obstruction after using Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity, time may be limited. District of Columbia's product liability statute of limitations is 3 years. Get a free, no-obligation evaluation today.
Free Case ReviewAdvertisement
Disclosure: NuLegal operates as a legal referral service. Attorney Ashkaan Hassan evaluates claims and refers qualified cases to specialized trial firms, earning a referral fee from the attorney's share of any recovery. Clients never pay out of pocket.